首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Trastuzumab deruxtecan for breast cancer. 曲妥珠单抗德鲁德替康治疗乳腺癌。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 Epub Date: 2022-06-07 DOI: 10.18773/austprescr.2022.043
{"title":"Trastuzumab deruxtecan for breast cancer.","authors":"","doi":"10.18773/austprescr.2022.043","DOIUrl":"https://doi.org/10.18773/austprescr.2022.043","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"146"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/99/austprescr-45-146.PMC9427624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer. 用于皮肤鳞状细胞癌、基底细胞癌、非小细胞肺癌。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.050
{"title":"Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer.","authors":"","doi":"10.18773/austprescr.2022.050","DOIUrl":"https://doi.org/10.18773/austprescr.2022.050","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"136-137"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/25/austprescr-45-136.PMC9427629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bimekizumab for plaque psoriasis. 比美珠单抗治疗斑块型银屑病。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.038
{"title":"Bimekizumab for plaque psoriasis.","authors":"","doi":"10.18773/austprescr.2022.038","DOIUrl":"https://doi.org/10.18773/austprescr.2022.038","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"132-133"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/49/austprescr-45-132.PMC9427631.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines not for everyone. 指导方针并不适合所有人。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.049
Shyan Goh
{"title":"Guidelines not for everyone.","authors":"Shyan Goh","doi":"10.18773/austprescr.2022.049","DOIUrl":"https://doi.org/10.18773/austprescr.2022.049","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"117"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/4d/austprescr-45-117.PMC9427622.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe adverse drug reaction to allopurinol. 别嘌呤醇严重不良反应。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.032
Grace Lucas, Luke Droney
{"title":"Severe adverse drug reaction to allopurinol.","authors":"Grace Lucas, Luke Droney","doi":"10.18773/austprescr.2022.032","DOIUrl":"https://doi.org/10.18773/austprescr.2022.032","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"130-131"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/2b/austprescr-45-130.PMC9427627.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The anticholinergic burden: from research to practice. 抗胆碱能负荷:从研究到实践。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.031
Sarah N Hilmer, Danijela Gnjidic

Drugs with anticholinergic effects are known to cause adverse effects such as dry mouth, constipation and urinary retention. In older people drugs with anticholinergic effects may contribute to cognitive decline and a loss of functional capacity. Many drugs that are not in the anticholinergic drug class also have anticholinergic effects. They include antidepressants, antipsychotics and antihistamines. Taking multiple drugs with anticholinergic effects creates an anticholinergic burden. It is important that clinicians identify which patients are at risk. There are several tools to assess the anticholinergic burden. Clinicians can use these tools to make a pharmacological risk assessment when reviewing a patient's medicines. This can assist decisions about continuing or stopping drugs with anticholinergic effects. Deprescribing drugs with anticholinergic effects has several potential benefits in older people. In addition to reversing adverse effects, deprescribing may prevent problems such as falls.

已知具有抗胆碱能作用的药物会引起诸如口干、便秘和尿潴留等不良反应。在老年人中,具有抗胆碱能作用的药物可能导致认知能力下降和功能丧失。许多不属于抗胆碱能药物类别的药物也具有抗胆碱能作用。它们包括抗抑郁药、抗精神病药和抗组胺药。服用多种具有抗胆碱能作用的药物会产生抗胆碱能负担。重要的是,临床医生要确定哪些患者处于危险之中。有几种评估抗胆碱能负荷的工具。临床医生可以使用这些工具在审查患者的药物时进行药理学风险评估。这有助于决定是否继续或停止具有抗胆碱能作用的药物。对老年人来说,解除抗胆碱能药物的处方有几个潜在的好处。除了扭转不良反应,开处方还可以预防跌倒等问题。
{"title":"The anticholinergic burden: from research to practice.","authors":"Sarah N Hilmer,&nbsp;Danijela Gnjidic","doi":"10.18773/austprescr.2022.031","DOIUrl":"https://doi.org/10.18773/austprescr.2022.031","url":null,"abstract":"<p><p>Drugs with anticholinergic effects are known to cause adverse effects such as dry mouth, constipation and urinary retention. In older people drugs with anticholinergic effects may contribute to cognitive decline and a loss of functional capacity. Many drugs that are not in the anticholinergic drug class also have anticholinergic effects. They include antidepressants, antipsychotics and antihistamines. Taking multiple drugs with anticholinergic effects creates an anticholinergic burden. It is important that clinicians identify which patients are at risk. There are several tools to assess the anticholinergic burden. Clinicians can use these tools to make a pharmacological risk assessment when reviewing a patient's medicines. This can assist decisions about continuing or stopping drugs with anticholinergic effects. Deprescribing drugs with anticholinergic effects has several potential benefits in older people. In addition to reversing adverse effects, deprescribing may prevent problems such as falls.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"118-120"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/5e/austprescr-45-118.PMC9427617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Erratum: Hormonal contraception and mood disorders [Correction]. 勘误:激素避孕和情绪障碍[更正]。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 Epub Date: 2022-06-23 DOI: 10.18773/austprescr.2022.037

[This corrects the article on p. 75 in vol. 45, PMID: 35755988.].

[这更正了第45卷第75页的文章,PMID: 35755988]。
{"title":"Erratum: Hormonal contraception and mood disorders [Correction].","authors":"","doi":"10.18773/austprescr.2022.037","DOIUrl":"https://doi.org/10.18773/austprescr.2022.037","url":null,"abstract":"<p><p>[This corrects the article on p. 75 in vol. 45, PMID: 35755988.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"147"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/93/austprescr-45-147.PMC9427623.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Elotuzumab for multiple myeloma. Elotuzumab用于多发性骨髓瘤。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.040
{"title":"Elotuzumab for multiple myeloma.","authors":"","doi":"10.18773/austprescr.2022.040","DOIUrl":"https://doi.org/10.18773/austprescr.2022.040","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"138-139"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/95/austprescr-45-138.PMC9427619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Off-label drugs for obesity. 标签外治疗肥胖的药物。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.046
Andy Morgan, Liz Sturgiss
The concluding statement ‘They [weight-loss drugs] are useful during the weight loss phase, but are essential in the maintenance phase’ is contentious but presented as fact. Despite these drugs being used for decades, there are still no trials reporting their benefit on end points, such as cardiovascular events and death. A Cochrane review of their longterm effects in people with hypertension found only one randomised trial reporting cardiovascular outcomes. This showed no differences in all-cause mortality or cardiovascular mortality or morbidity.2
{"title":"Off-label drugs for obesity.","authors":"Andy Morgan,&nbsp;Liz Sturgiss","doi":"10.18773/austprescr.2022.046","DOIUrl":"https://doi.org/10.18773/austprescr.2022.046","url":null,"abstract":"The concluding statement ‘They [weight-loss drugs] are useful during the weight loss phase, but are essential in the maintenance phase’ is contentious but presented as fact. Despite these drugs being used for decades, there are still no trials reporting their benefit on end points, such as cardiovascular events and death. A Cochrane review of their longterm effects in people with hypertension found only one randomised trial reporting cardiovascular outcomes. This showed no differences in all-cause mortality or cardiovascular mortality or morbidity.2","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"114"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/6a/austprescr-45-114.PMC9427632.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium-glucose co-transporter 2 inhibitors beyond diabetes. 糖尿病以外的钠-葡萄糖共转运蛋白2抑制剂。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.036
Dimity L Williams, Serena Rofail, John J Atherton

Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease. This led to further trials that included patients without diabetes. In studies of heart failure, SGLT2 inhibitors were beneficial in treating patients with a reduced left ventricular ejection fraction. A recent study has also reported benefits in patients with a preserved ejection fraction. In chronic kidney disease, SGLT2 inhibitors may reduce disease progression. However, a decline in the glomerular filtration rate may be seen at the start of treatment. As most experience with SGLT2 inhibitors is in diabetes, patients without diabetes need to be aware of why they are being prescribed these drugs. Some of the potential indications for SGLT2 inhibitors beyond diabetes are not yet approved by regulatory authorities.

钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂通过减少葡萄糖在肾脏中的重吸收来降低血糖。它们是治疗2型糖尿病的二线药物。在临床试验中,人们注意到SGLT2抑制剂对心血管和肾脏疾病有良好的影响。这导致了进一步的试验,包括没有糖尿病的患者。在心力衰竭的研究中,SGLT2抑制剂对治疗左心室射血分数降低的患者有益。最近的一项研究也报告了保留射血分数的患者的益处。在慢性肾脏疾病中,SGLT2抑制剂可能会减缓疾病进展。然而,肾小球滤过率在治疗开始时可能出现下降。由于大多数使用SGLT2抑制剂的患者是糖尿病患者,因此没有糖尿病的患者需要了解他们为什么要开这些药。除糖尿病外,SGLT2抑制剂的一些潜在适应症尚未得到监管机构的批准。
{"title":"Sodium-glucose co-transporter 2 inhibitors beyond diabetes.","authors":"Dimity L Williams,&nbsp;Serena Rofail,&nbsp;John J Atherton","doi":"10.18773/austprescr.2022.036","DOIUrl":"https://doi.org/10.18773/austprescr.2022.036","url":null,"abstract":"<p><p>Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease. This led to further trials that included patients without diabetes. In studies of heart failure, SGLT2 inhibitors were beneficial in treating patients with a reduced left ventricular ejection fraction. A recent study has also reported benefits in patients with a preserved ejection fraction. In chronic kidney disease, SGLT2 inhibitors may reduce disease progression. However, a decline in the glomerular filtration rate may be seen at the start of treatment. As most experience with SGLT2 inhibitors is in diabetes, patients without diabetes need to be aware of why they are being prescribed these drugs. Some of the potential indications for SGLT2 inhibitors beyond diabetes are not yet approved by regulatory authorities.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"121-124"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/05/austprescr-45-121.PMC9427625.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1